Pharmacoepidemiologic analysis outpatient treatment of bronchial asthma (BA) Source: Eur Respir J 2005; 26: Suppl. 49, 384s Year: 2005
The effect of adding inhaled corticosteroids to long-acting bronchodilators for COPD: A real practice analysis in Italy Source: International Congress 2014 – Prevalence of COPD and mortality from COPD Year: 2014
Pharmacoepidemiological analysis of the treatment of bronchial asthma patients Source: Eur Respir J 2005; 26: Suppl. 49, 683s Year: 2005
Treatment with inhaled corticosteroids (ICS), smoking and asthma control in real clinical practice Source: Annual Congress 2010 - Pharmacological treatment in primary care Year: 2010
Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Trends of short-acting beta-agonist (SABA) surrounding days of high use in asthma and COPD Source: International Congress 2019 – Exacerbations and clinical impact of airway diseases Year: 2019
Treatment of asthma the current European perspective Source: Annual Congress 2006 - Childhood asthma therapy: where we are now and where we need to go Year: 2006
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD Source: Annual Congress 2013 –Risk factors for COPD and lung function decline Year: 2013
Use of inhalation corticosteroids (ICS) in children with asthma in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 395s Year: 2002
Pattern of asthma control and inhaled corticosteroid (ICS) use in an Australian asthma population Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Cost-effectivness of transition to new strategy of treatment in patients with bronchial asthma (BA) in Russia Source: Eur Respir J 2001; 18: Suppl. 33, 44s Year: 2001
Cost-effectiveness of transition to new strategy of treatment in patients with bronchial asthma (BA) in Russia Source: Eur Respir J 2002; 20: Suppl. 38, 56s Year: 2002
Cost-minimisation analysis of two different inhaled steroids in persistent bronchial asthma Source: Eur Respir J 2002; 20: Suppl. 38, 302s Year: 2002
Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015
First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004
Airways diseases: influential developments in the past 5 years Source: Annual Congress 2005 - PG14 - Moving on from the Millennium: developing trends in respiratory medicine (jointly organised with ACCP) Year: 2005
Suboptimal persistence with inhaled corticosteroid (ICS) mono-therapy among children with persistent asthma in the UK Source: Eur Respir J 2006; 28: Suppl. 50, 709s Year: 2006
Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004
Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence? Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020